Senti Biosciences, Inc.
SNTIHealthcare|Biotechnology|US
$0.16
-0.00 (-2.74%)
Cash / Share
$0.21
Financials
Financial Snapshot
Market Cap
$5.0M
Enterprise Value
$18.7M
Revenue (TTM)
$55.0K
Net Income (TTM)
-$49.6M
Cash & Investments
$6.5M
Net Cash
-$13.8M
Free Cash Flow (TTM)
-$38.1M
Operating CF (TTM)
-$38.1M
Debt/Equity
-5.95
Cash Runway & Burn Rate
Cash on Hand
$6.5M
Quarterly Burn
$9.5M
Monthly Burn
$3.2M
Est. Runway
~0.7 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $17.8M | $30.5M | $56.0M | $98.6M | $35.9M | $48.3M | $16.4M | $6.5M | |
| Operating Cash Flow | -$18.4M | -$24.2M | -$34.6M | -$34.9M | -$52.4M | -$41.4M | -$43.4M | -$38.1M | |
| Free Cash Flow | -$20.4M | -$25.3M | -$40.2M | -$76.3M | -$64.4M | -$41.4M | -$43.6M | -$38.1M | |
| Capital Expenditure | -$2.0M | -$1.2M | -$5.5M | -$41.4M | -$12.0M | -$26.0K | -$196.0K | $0.00 | |
| Financing Cash Flow | $14.0M | $38.1M | $68.4M | $118.6M | $779.0K | $53.7M | $11.8M | $20.7M |
R&D Spending
R&D (TTM)
$31.3M
R&D Intensity
56952.7%
R&D Growth vs Prior
-16.7%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85.0K | $394.0K | $2.3M | $3.3M | $2.0M | $0.00 | $22.0K | $55.0K | |
| R&D Expense | $14.5M | $16.0M | $22.0M | $28.1M | $32.1M | $34.4M | $37.6M | $31.3M | |
| R&D % of Revenue | 17087.1% | 4049.7% | 958.4% | 856.5% | 1625.4% | — | 170845.5% | 56952.7% | |
| SG&A | $7.3M | $9.3M | $21.3M | $37.6M | $34.9M | $23.5M | $26.2M | $24.1M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85.0K | $394.0K | $2.3M | $3.3M | $2.0M | $0.00 | $22.0K | $55.0K | |
| Cost of Revenue | $14.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.6M | $1.6M | |
| Gross Profit | -$14.4M | $394.0K | $2.3M | $3.3M | $2.0M | $0.00 | -$3.6M | -$1.5M | |
| R&D | $14.5M | $16.0M | $22.0M | $28.1M | $32.1M | $34.4M | $37.6M | $31.3M | |
| SG&A | $7.3M | $9.3M | $21.3M | $37.6M | $34.9M | $23.5M | $26.2M | $24.1M | |
| Operating Income | -$21.8M | -$24.7M | -$40.4M | -$62.1M | -$92.7M | -$61.0M | -$63.7M | -$56.5M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$21.2M | -$19.9M | -$55.3M | -$49.7M | -$83.4M | -$52.8M | -$61.4M | -$49.6M | |
| Net Income | -$21.2M | -$19.9M | -$55.3M | -$58.2M | -$71.1M | -$52.8M | -$61.4M | -$49.6M | |
| EPS (Diluted) | -15.57 | -4.55 | -12.67 | -13.25 | -20.94 | -11.49 | -2.73 | -1.77 | |
| EBITDA | -$20.4M | -$22.7M | -$52.3M | -$45.7M | -$61.3M | -$54.9M | -$57.8M | -$47.0M | |
| Shares Out. (M) | 1.36 | 4.37 | 4.37 | 4.39 | 4.44 | 4.60 | 224.83 | 31.14 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.3M | $30.5M | $56.0M | $57.6M | $35.9M | $48.3M | $16.4M | $6.5M | |
| Short-Term Investments | $12.5M | $0.00 | $0.00 | $40.9M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $18.8M | $31.7M | $58.7M | $102.6M | $71.2M | $59.0M | $23.3M | $13.0M | |
| Total Assets | $35.8M | $48.3M | $96.7M | $180.8M | $119.5M | $97.8M | $51.2M | $33.1M | |
| Total Current Liabilities | $4.3M | $4.9M | $14.5M | $18.1M | $12.7M | $13.1M | $14.0M | $15.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $17.9M | $107.1M | $36.3M | $53.5M | $52.6M | $72.2M | $45.6M | $36.5M | |
| Stockholders' Equity | $18.0M | -$58.7M | $60.4M | $127.3M | $66.9M | $25.6M | $5.6M | -$3.4M | |
| Retained Earnings | -$39.9M | -$59.8M | -$115.1M | -$173.3M | -$244.3M | -$297.1M | -$358.6M | -$375.5M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.4M | -$24.2M | -$34.6M | -$34.9M | -$52.4M | -$41.4M | -$43.4M | -$38.1M | |
| Capital Expenditure | -$2.0M | -$1.2M | -$5.5M | -$41.4M | -$12.0M | -$26.0K | -$196.0K | $0.00 | |
| Free Cash Flow | -$20.4M | -$25.3M | -$40.2M | -$76.3M | -$64.4M | -$41.4M | -$43.6M | -$38.1M | |
| Investing Cash Flow | $3.8M | $11.4M | -$5.5M | -$82.0M | $30.1M | $34.0K | -$184.0K | $126.0K | |
| Financing Cash Flow | $14.0M | $38.1M | $68.4M | $118.6M | $779.0K | $53.7M | $11.8M | $20.7M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $728.0K | $512.0K | $49.1M | $8.7M | $10.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $8.0M | $0.00 | $5.2M | -$108.0K | $0.00 | $0.00 | $9.7M | |
| Stock Based Comp. | $205.0K | $272.0K | $2.3M | $16.4M | $9.7M | $1.8M | $5.7M | $5.3M | |
| Net Change in Cash | $5.8M | $25.2M | $28.3M | $1.7M | -$21.5M | $12.4M | -$31.9M | -$17.2M |
Dilution Tracker
Shares outstanding grew 5050.0% over 5 years — significant dilution
Shares Outstanding
31M
5-Year Share Growth
+5050.0%
Stock Issuance (TTM)
$10.6M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.36 | 4.37 | 4.37 | 4.39 | 4.44 | 4.60 | 224.83 | 31.14 | |
| Change vs Prior % | — | 221.3% | 0.0% | 0.7% | 1.0% | 3.6% | 4791.9% | -86.1% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $728.0K | $512.0K | $49.1M | $8.7M | $10.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $205.0K | $272.0K | $2.3M | $16.4M | $9.7M | $1.8M | $5.7M | $5.3M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -16987.1% | 100.0% | 100.0% | 100.0% | 100.0% | — | -16431.8% | -2736.4% | |
| Operating Margin % | -25625.9% | -6267.5% | -1765.4% | -1889.3% | -4687.9% | — | -289668.2% | -102761.8% | |
| Net Margin % | -24890.6% | -5041.1% | -2414.6% | -1771.5% | -3592.4% | — | -279263.6% | -90116.4% | |
| EBITDA Margin % | -23983.5% | -5763.7% | -2283.2% | -1392.1% | -3100.9% | — | -262731.8% | -85405.5% | |
| FCF Margin % | -23969.4% | -6429.9% | -1753.7% | -2321.1% | -3257.5% | — | -198363.6% | -69183.6% | |
| ROE % | -117.8% | 33.8% | -91.6% | -45.7% | -106.2% | -205.8% | -1099.3% | -1540.0% | |
| ROA % | -59.0% | -41.1% | -57.2% | -32.2% | -59.5% | -54.0% | -119.9% | -149.7% | |
| ROIC % | -70.2% | -54.9% | -48.2% | -37.7% | -83.6% | -68.2% | -149.7% | -227.7% | |
| R&D / Revenue % | 17087.1% | 4049.7% | 958.4% | 856.5% | 1625.4% | — | 170845.5% | 56952.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 363.5% | 481.5% | 43.4% | -39.8% | -100.0% | 0.0% | |
| Gross Profit | 0.0% | 102.7% | 481.5% | 43.4% | -39.8% | -100.0% | 0.0% | |
| Operating Income | 0.0% | -13.4% | -63.8% | -53.5% | -49.4% | 34.2% | -4.4% | |
| Net Income | 0.0% | 6.1% | -178.5% | -5.2% | -22.1% | 25.7% | -16.4% | |
| EPS (Diluted) | 0.0% | 70.8% | -178.5% | -4.6% | -58.0% | 45.1% | 76.2% | |
| Operating Cash Flow | 0.0% | -31.5% | -43.3% | -0.8% | -50.1% | 21.0% | -4.9% | |
| Free Cash Flow | 0.0% | -24.3% | -58.6% | -89.8% | 15.5% | 35.7% | -5.4% | |
| R&D Expense | 0.0% | 9.9% | 37.6% | 28.2% | 14.2% | 6.9% | 9.4% | |
| SG&A Expense | 0.0% | 26.7% | 128.4% | 77.1% | -7.3% | -32.6% | 11.3% | |
| Total Assets | 0.0% | 34.9% | 100.0% | 87.0% | -33.9% | -18.1% | -47.6% | |
| Book Value / Share | 0.0% | -201.7% | 202.8% | 109.4% | -47.9% | -63.0% | -99.6% | |
| Debt | 0.0% | 0.0% | 61.8% | 63.2% | 1.6% | -10.7% | -14.1% | |
| Diluted Shares | 0.0% | 221.3% | 0.0% | 0.7% | 1.0% | 3.6% | 4791.9% |
Valuation
P/E (TTM)At Loss
P/S90.60
10Y Low / Med / High14.81 / 1105.83 / 10628.51
P/B-1.47
10Y Low / Med / High0.44 / 7.13 / 41.84
EV/EBITDAAt Loss
EV/Revenue340.84
10Y Low / Med / High12.61 / 1063.98 / 11195.38
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.21
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -6.41 | -21.93 | -7.78 | -1.06 | -0.32 | -0.31 | -0.38 | -0.09 | |
| P/S Ratio | 1595.26 | 1105.83 | 187.89 | 18.86 | 14.81 | 0.00 | 10628.51 | 90.60 | |
| P/B Ratio | 7.55 | -7.42 | 7.13 | 0.49 | 0.44 | 0.63 | 41.84 | -1.47 | |
| EV/EBITDA | -6.39 | -18.46 | -7.59 | -0.91 | -0.51 | -0.03 | -4.26 | -0.40 | |
| EV/Revenue | 1532.90 | 1063.98 | 173.35 | 12.61 | 15.69 | 0.00 | 11195.38 | 340.84 |
Analyst Estimates & Quality
Altman Z-Score
-20.89
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $16.0K | $100.0K | $20.6M |
| Net Income | -$175.4M | -$215.8M | -$362.0M |
| EPS | $-0.78 | $-0.96 | $-1.61 |
| # Analysts (EPS) | 1 | 1 | 2 |
Revenue Segments
By Product
| Segment | 2022 | 2025 |
|---|---|---|
| License | $800.0K | — |
| Reportable Segment | — | $22.0K |